Catiele Antunes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Catiele Antunes has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Diogo Onofre Souza
Universidade Federal do Rio Grande do Sul
4 shared publications - Elaine Elisabetsky
Universidade Federal do Rio Grande do Sul
4 shared publications AP Schmidt
Department of Biochemistry, ICBS, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
2 shared publicationsAe Böhmer
Department of Biochemistry, ICBS, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
2 shared publicationsAna Elisa Böhmer
2 shared publications- André Schmidt
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde (ICBS), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
2 shared publications
Latest Publications
- 17 October 2026
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 50 (9)
Beyond CT-defined low muscle mass in cirrhosis: toward a more accessible diagnostic approach
- 17 October 2026
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 50 (9)
Beyond CT-defined low muscle mass in cirrhosis: toward a more accessible diagnostic approach
- Open Access
- 13 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (8) , 1866-1874
Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Nonerosive Reflux Disease
INTRODUCTION: This analysis of a phase 3 randomized trial evaluated the efficacy of vonoprazan on prespecified end points for nighttime symptoms in patients with nonerosive reflux disease. METHODS: Adults with heartburn ≥4 d/wk and without erosive esophagitis were randomized to placebo, vonoprazan 10 mg, or vonoprazan 20 mg. After 4 weeks, subjects on placebo were rerandomized to vonoprazan 10 or 20 mg, and those already on vonoprazan continued the same dose for an additional 20 weeks. Nocturnal Gastro-esophageal Reflux Disease Symptom Severity and Impact Questionnaire (N-GSSIQ), a validated instrument for nocturnal gastroesophageal reflux disease, was completed at baseline and weeks 4, 12, and 24. Minimal important differences for N-GSSIQ total score and subscales were defined as ≥0.4. RESULTS: Among 772 subjects, the mean percentage of heartburn-free nights at week 4 was 43.3% for placebo vs 59.9% for vonoprazan 10 mg (least squares [LS] mean difference = 16.5%, P < 0.0001) and 56.4% for vonoprazan 20 mg (LS mean difference, 13.1%, P < 0.0001). Vonoprazan improved N-GSSIQ total score (LS mean difference vs placebo of −2.9 and −1.8 for vonoprazan 10 and 20 mg, respectively; P < 0.005 for both comparisons), nocturnal symptom severity subscale (LS mean difference vs placebo of −5.4 and −3.5 for vonoprazan 10 and 20 mg; P < 0.001 for both comparisons), and concern about nocturnal gastroesophageal reflux disease subscale (LS mean difference vs placebo of −2.0 for both vonoprazan 10 and 20 mg; P < 0.0001). The benefit on heartburn-free nights and N-GSSIQ scores was observed through the additional 20 weeks. DISCUSSION: Our study suggests that vonoprazan leads to relief of nighttime heartburn in patients with heartburn and a normal endoscopy.
- 13 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (8) , 1866-1874
Open AccessVonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Nonerosive Reflux Disease
INTRODUCTION: This analysis of a phase 3 randomized trial evaluated the efficacy of vonoprazan on prespecified end points for nighttime symptoms in patients with nonerosive reflux disease. METHODS: Adults with heartburn ≥4 d/wk and without erosive esophagitis were randomized to placebo, vonoprazan 10 mg, or vonoprazan 20 mg. After 4 weeks, subjects on placebo were rerandomized to vonoprazan 10 or 20 mg, and those already on vonoprazan continued the same dose for an additional 20 weeks. Nocturnal Gastro-esophageal Reflux Disease Symptom Severity and Impact Questionnaire (N-GSSIQ), a validated instrument for nocturnal gastroesophageal reflux disease, was completed at baseline and weeks 4, 12, and 24. Minimal important differences for N-GSSIQ total score and subscales were defined as ≥0.4. RESULTS: Among 772 subjects, the mean percentage of heartburn-free nights at week 4 was 43.3% for placebo vs 59.9% for vonoprazan 10 mg (least squares [LS] mean difference = 16.5%, P < 0.0001) and 56.4% for vonoprazan 20 mg (LS mean difference, 13.1%, P < 0.0001). Vonoprazan improved N-GSSIQ total score (LS mean difference vs placebo of −2.9 and −1.8 for vonoprazan 10 and 20 mg, respectively; P < 0.005 for both comparisons), nocturnal symptom severity subscale (LS mean difference vs placebo of −5.4 and −3.5 for vonoprazan 10 and 20 mg; P < 0.001 for both comparisons), and concern about nocturnal gastroesophageal reflux disease subscale (LS mean difference vs placebo of −2.0 for both vonoprazan 10 and 20 mg; P < 0.0001). The benefit on heartburn-free nights and N-GSSIQ scores was observed through the additional 20 weeks. DISCUSSION: Our study suggests that vonoprazan leads to relief of nighttime heartburn in patients with heartburn and a normal endoscopy.
- 8 November 2023
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 25 (12) , 363-373
Esophageal Radiography Interpretation: a Primer for the Gastroenterologist
Purpose of Review Radiological studies can be helpful when evaluating patients with suspect esophageal disorders. From benign strictures to malignancy and motility disorders such as achalasia, imaging modalities play a significant role in diagnosis. This review explores the role of different imaging modalities in the most frequently encountered esophageal pathologies. Recent Findings Conventional barium esophagram has long been considered the primary imaging modality of the esophagus. In the same fashion, a timed barium esophagram is a valuable tool in the evaluation of achalasia and esophagogastric junction outlet obstruction. Over the last few decades there has been an increase in CT and MRI studies, which also play a role in the evaluation of esophageal pathologies. However, not infrequently, these newer imaging techniques can result in incidental esophageal findings. It is important that gastroenterologists appreciate the value of different modalities and recognize key imaging features. Summary The diagnosis and management of esophageal disorders is evolving. A basic understanding of esophageal radiology is essential to any gastroenterologist caring for patients with esophageal complaints.
- 8 November 2023
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 25 (12) , 363-373
Esophageal Radiography Interpretation: a Primer for the Gastroenterologist
Purpose of Review Radiological studies can be helpful when evaluating patients with suspect esophageal disorders. From benign strictures to malignancy and motility disorders such as achalasia, imaging modalities play a significant role in diagnosis. This review explores the role of different imaging modalities in the most frequently encountered esophageal pathologies. Recent Findings Conventional barium esophagram has long been considered the primary imaging modality of the esophagus. In the same fashion, a timed barium esophagram is a valuable tool in the evaluation of achalasia and esophagogastric junction outlet obstruction. Over the last few decades there has been an increase in CT and MRI studies, which also play a role in the evaluation of esophageal pathologies. However, not infrequently, these newer imaging techniques can result in incidental esophageal findings. It is important that gastroenterologists appreciate the value of different modalities and recognize key imaging features. Summary The diagnosis and management of esophageal disorders is evolving. A basic understanding of esophageal radiology is essential to any gastroenterologist caring for patients with esophageal complaints.
- Open Access
- 1 September 2010
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 30 (35) , 11815-11825
Agrp Neurons Mediate Sirt1's Action on the Melanocortin System and Energy Balance: Roles for Sirt1 in Neuronal Firing and Synaptic Plasticity
Sirt1 has been associated with various effects of calorie restriction, including an increase in lifespan. Here we show in mice that a central regulatory component in energy metabolism, the hypothalamic melanocortin system, is affected by Sirt1, which promotes the activity and connectivity of this system resulting in negative energy balance. In adult mice, the pharmacological inhibition of brain Sirt1 activity decreased Agrp neuronal activity and the inhibitory tone on the anorexigenic POMC neurons, as measured by the number of synaptic inputs to these neurons. When a Sirt1 inhibitor (EX-527) was injected either peripherally (i.p., 10 mg/kg) or directly into the brain (i.c.v., 1.5 nmol/mouse), it decreased both food intake during the dark cycle and ghrelin-induced food intake. This effect on feeding is mediated by upstream melanocortin receptors, because the MC4R antagonist, SHU9119, reversed Sirt1's effect on food intake. This action of Sirt1 required an appropriate shift in the mitochondrial redox state: in the absence of such an adaptation enabled by the mitochondrial protein, UCP2, Sirt1-induced cellular and behavioral responses were impaired. In accordance with the pharmacological results, the selective knock-out of Sirt1 in hypothalamic Agrp neurons through the use of Cre-Lox technology decreased electric responses of Agrp neurons to ghrelin and decreased food intake, leading to decreased lean mass, fat mass, and body weight. The present data indicate that Sirt1 has a central mode of action by acting on the NPY/Agrp neurons to affect body metabolism.
- 1 September 2010
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 30 (35) , 11815-11825
Open AccessAgrp Neurons Mediate Sirt1's Action on the Melanocortin System and Energy Balance: Roles for Sirt1 in Neuronal Firing and Synaptic Plasticity
Sirt1 has been associated with various effects of calorie restriction, including an increase in lifespan. Here we show in mice that a central regulatory component in energy metabolism, the hypothalamic melanocortin system, is affected by Sirt1, which promotes the activity and connectivity of this system resulting in negative energy balance. In adult mice, the pharmacological inhibition of brain Sirt1 activity decreased Agrp neuronal activity and the inhibitory tone on the anorexigenic POMC neurons, as measured by the number of synaptic inputs to these neurons. When a Sirt1 inhibitor (EX-527) was injected either peripherally (i.p., 10 mg/kg) or directly into the brain (i.c.v., 1.5 nmol/mouse), it decreased both food intake during the dark cycle and ghrelin-induced food intake. This effect on feeding is mediated by upstream melanocortin receptors, because the MC4R antagonist, SHU9119, reversed Sirt1's effect on food intake. This action of Sirt1 required an appropriate shift in the mitochondrial redox state: in the absence of such an adaptation enabled by the mitochondrial protein, UCP2, Sirt1-induced cellular and behavioral responses were impaired. In accordance with the pharmacological results, the selective knock-out of Sirt1 in hypothalamic Agrp neurons through the use of Cre-Lox technology decreased electric responses of Agrp neurons to ghrelin and decreased food intake, leading to decreased lean mass, fat mass, and body weight. The present data indicate that Sirt1 has a central mode of action by acting on the NPY/Agrp neurons to affect body metabolism.
- Open Access
- 1 August 2010
- Published by FapUNIFESP (SciELO) in Revista do Colégio Brasileiro de Cirurgiões
- Vol. 37 (4) , 288-294
Efeitos do cloreto de gadolínio na pancreatite induzida por tauracolato de sódio em ratos
OBJETIVO: Avaliar os efeitos do uso de cloreto de gadolínio como pré-tratamento e tratamento em um modelo experimental de pancreatite em ratos induzida por tauracolato de sódio a 3%. MÉTODOS: Ratos Wistar foram divididos em cinco grupos: grupo SF - controle com solução fisiológica intra-ductal e IV; grupo TS - controle com PA induzida por tauracolato de sódio a 3% e solução fisiológica a 0,9% IV; grupo GD - controle com SF intra-ductal e cloreto de gadolínio IV; grupo GDTS - pré-tratamento com GD (24h antes da indução da PA) e grupo TSGD - tratamento com GD (1h após a indução da PA). Foi realizado dosagem sérica de amilase, transaminases e TNF-á; determinação da atividade da MPO no tecido pulmonar; histologia pancreática e pulmonar. RESULTADOS: O número de animais mortos antes do término previsto do experimento foi significativamente maior no grupo TSGD (p=0,046). Os escores de pancreatite e de dano pulmonar foram mais elevados nos grupos que utilizaram tauracolato em comparação aos grupos com infusão intra-ductal de solução salina. Não houve diferenças nas demais variáveis estudadas na comparação entre os grupos TS; GDTS e TSGD. CONCLUSÃO: Não foram demonstrados benefícios com o uso de cloreto de gadolínio de forma profilática e terapêutica.
- 1 August 2010
- Published by FapUNIFESP (SciELO) in Revista do Colégio Brasileiro de Cirurgiões
- Vol. 37 (4) , 288-294
Open AccessEfeitos do cloreto de gadolínio na pancreatite induzida por tauracolato de sódio em ratos
OBJETIVO: Avaliar os efeitos do uso de cloreto de gadolínio como pré-tratamento e tratamento em um modelo experimental de pancreatite em ratos induzida por tauracolato de sódio a 3%. MÉTODOS: Ratos Wistar foram divididos em cinco grupos: grupo SF - controle com solução fisiológica intra-ductal e IV; grupo TS - controle com PA induzida por tauracolato de sódio a 3% e solução fisiológica a 0,9% IV; grupo GD - controle com SF intra-ductal e cloreto de gadolínio IV; grupo GDTS - pré-tratamento com GD (24h antes da indução da PA) e grupo TSGD - tratamento com GD (1h após a indução da PA). Foi realizado dosagem sérica de amilase, transaminases e TNF-á; determinação da atividade da MPO no tecido pulmonar; histologia pancreática e pulmonar. RESULTADOS: O número de animais mortos antes do término previsto do experimento foi significativamente maior no grupo TSGD (p=0,046). Os escores de pancreatite e de dano pulmonar foram mais elevados nos grupos que utilizaram tauracolato em comparação aos grupos com infusão intra-ductal de solução salina. Não houve diferenças nas demais variáveis estudadas na comparação entre os grupos TS; GDTS e TSGD. CONCLUSÃO: Não foram demonstrados benefícios com o uso de cloreto de gadolínio de forma profilática e terapêutica.
- Open Access
- 12 March 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (6) , 1247-1263
Mechanisms involved in the antinociception induced by systemic administration of guanosine in mice
Background and purpose: It is well known that adenine‐based purines exert multiple effects on pain transmission. However, less attention has been given to the potential effects of guanine‐based purines on pain transmission. The aim of this study was to investigate the effects of intraperitoneal (i.p.) and oral (p.o.) administration of guanosine on mice pain models. Additionally, investigation into the mechanisms of action of guanosine, its potential toxicity and cerebrospinal fluid (CSF) purine levels were also assessed.Experimental approach: Mice received an i.p. or p.o. administration of vehicle (0.1 mM NaOH) or guanosine (up to 240 mg·kg−1) and were evaluated in several pain models.Key results: Guanosine produced dose‐dependent antinociceptive effects in the hot‐plate, glutamate, capsaicin, formalin and acetic acid models, but it was ineffective in the tail‐flick test. Additionally, guanosine produced a significant inhibition of biting behaviour induced by i.t. injection of glutamate, AMPA, kainate and trans‐ACPD, but not against NMDA, substance P or capsaicin. The antinociceptive effects of guanosine were prevented by selective and non‐selective adenosine receptor antagonists. Systemic administration of guanosine (120 mg·kg−1) induced an approximately sevenfold increase on CSF guanosine levels. Guanosine prevented the increase on spinal cord glutamate uptake induced by intraplantar capsaicin.Conclusions and implications: This study provides new evidence on the mechanism of action of the antinociceptive effects after systemic administration of guanosine. These effects seem to be related to the modulation of adenosine A1and A2Areceptors and non‐NMDA glutamate receptors.
- 12 March 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (6) , 1247-1263
Open AccessMechanisms involved in the antinociception induced by systemic administration of guanosine in mice
Background and purpose: It is well known that adenine‐based purines exert multiple effects on pain transmission. However, less attention has been given to the potential effects of guanine‐based purines on pain transmission. The aim of this study was to investigate the effects of intraperitoneal (i.p.) and oral (p.o.) administration of guanosine on mice pain models. Additionally, investigation into the mechanisms of action of guanosine, its potential toxicity and cerebrospinal fluid (CSF) purine levels were also assessed.Experimental approach: Mice received an i.p. or p.o. administration of vehicle (0.1 mM NaOH) or guanosine (up to 240 mg·kg−1) and were evaluated in several pain models.Key results: Guanosine produced dose‐dependent antinociceptive effects in the hot‐plate, glutamate, capsaicin, formalin and acetic acid models, but it was ineffective in the tail‐flick test. Additionally, guanosine produced a significant inhibition of biting behaviour induced by i.t. injection of glutamate, AMPA, kainate and trans‐ACPD, but not against NMDA, substance P or capsaicin. The antinociceptive effects of guanosine were prevented by selective and non‐selective adenosine receptor antagonists. Systemic administration of guanosine (120 mg·kg−1) induced an approximately sevenfold increase on CSF guanosine levels. Guanosine prevented the increase on spinal cord glutamate uptake induced by intraplantar capsaicin.Conclusions and implications: This study provides new evidence on the mechanism of action of the antinociceptive effects after systemic administration of guanosine. These effects seem to be related to the modulation of adenosine A1and A2Areceptors and non‐NMDA glutamate receptors.
- 1 February 2010
- Published by Elsevier in Experimental Neurology
- Vol. 221 (2) , 296-306
Electrophysiological effects of guanosine and MK-801 in a quinolinic acid-induced seizure model
- 1 February 2010
- Published by Elsevier in Experimental Neurology
- Vol. 221 (2) , 296-306
Electrophysiological effects of guanosine and MK-801 in a quinolinic acid-induced seizure model
- 1 June 2009
- Published by Elsevier in European Journal of Pharmacology
- Vol. 613 (1-3) , 46-53
Spinal mechanisms of antinociceptive action caused by guanosine in mice
- 1 June 2009
- Published by Elsevier in European Journal of Pharmacology
- Vol. 613 (1-3) , 46-53
Spinal mechanisms of antinociceptive action caused by guanosine in mice
- Open Access
- 24 December 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 156 (1) , 163-172
Anti‐nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1adenosine receptors
Background and purpose: Allopurinol is a potent inhibitor of the enzyme xanthine oxidase, used primarily in the treatment of hyperuricemia and gout. It is well known that purines exert multiple effects on pain transmission. We hypothesized that the inhibition of xanthine oxidase by allopurinol, thereby reducing purine degradation, could be a valid strategy to enhance purinergic activity. The aim of this study was to investigate the anti‐nociceptive profile of allopurinol on chemical and thermal pain models in mice.Experimental approach: Mice received an intraperitoneal (i.p.) injection of vehicle (Tween 10%) or allopurinol (10–400 mg kg−1). Anti‐nociceptive effects were measured with intraplantar capsaicin, intraplantar glutamate, tail‐flick or hot‐plate tests.Key results: Allopurinol presented dose‐dependent anti‐nociceptive effects in all models. The opioid antagonist naloxone did not affect these anti‐nociceptive effects. The non‐selective adenosine‐receptor antagonist caffeine and the selective A1adenosine‐receptor antagonist, DPCPX, but not the selective A2Aadenosine‐receptor antagonist, SCH58261, completely prevented allopurinol‐induced anti‐nociception. No obvious motor deficits were produced by allopurinol, at doses up to 200 mg kg−1. Allopurinol also caused an increase in cerebrospinal fluid levels of purines, including the nucleosides adenosine and guanosine, and decreased cerebrospinal fluid concentration of uric acid.Conclusions and implications: Allopurinol‐induced anti‐nociception may be related to adenosine accumulation. Allopurinol is an old and extensively used compound and seems to be well tolerated with no obvious central nervous system toxic effects at high doses. This drug may be useful to treat pain syndromes in humans.
- 24 December 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 156 (1) , 163-172
Open AccessAnti‐nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1adenosine receptors
Background and purpose: Allopurinol is a potent inhibitor of the enzyme xanthine oxidase, used primarily in the treatment of hyperuricemia and gout. It is well known that purines exert multiple effects on pain transmission. We hypothesized that the inhibition of xanthine oxidase by allopurinol, thereby reducing purine degradation, could be a valid strategy to enhance purinergic activity. The aim of this study was to investigate the anti‐nociceptive profile of allopurinol on chemical and thermal pain models in mice.Experimental approach: Mice received an intraperitoneal (i.p.) injection of vehicle (Tween 10%) or allopurinol (10–400 mg kg−1). Anti‐nociceptive effects were measured with intraplantar capsaicin, intraplantar glutamate, tail‐flick or hot‐plate tests.Key results: Allopurinol presented dose‐dependent anti‐nociceptive effects in all models. The opioid antagonist naloxone did not affect these anti‐nociceptive effects. The non‐selective adenosine‐receptor antagonist caffeine and the selective A1adenosine‐receptor antagonist, DPCPX, but not the selective A2Aadenosine‐receptor antagonist, SCH58261, completely prevented allopurinol‐induced anti‐nociception. No obvious motor deficits were produced by allopurinol, at doses up to 200 mg kg−1. Allopurinol also caused an increase in cerebrospinal fluid levels of purines, including the nucleosides adenosine and guanosine, and decreased cerebrospinal fluid concentration of uric acid.Conclusions and implications: Allopurinol‐induced anti‐nociception may be related to adenosine accumulation. Allopurinol is an old and extensively used compound and seems to be well tolerated with no obvious central nervous system toxic effects at high doses. This drug may be useful to treat pain syndromes in humans.
- 1 October 2008
- Published by Elsevier in Brain Research
- Vol. 1234, 50-58
Antinociceptive effects of intracerebroventricular administration of guanine-based purines in mice: Evidences for the mechanism of action
- 1 October 2008
- Published by Elsevier in Brain Research
- Vol. 1234, 50-58
Antinociceptive effects of intracerebroventricular administration of guanine-based purines in mice: Evidences for the mechanism of action